Lenvatinib (Kisplyx®) is accepted for use within NHS Scotland

Source:
Scottish Medicines Consortium - SMC
Publisher:
Scottish Medicines Consortium
Publication date:
11 November 2019

Abstract

Lenvatinib is approved for use in NHS Scotland, in combination with everolimus for the treatment of adult patients with advanced renal cell carcinoma following one prior vascular endothelial growth factor (VEGF)-targeted therapy.